Clinical Data Another LAG-3 setback as Regeneron drug fails phase 3 trial PharmaphorumRegeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.OncologyRead full story pharminent May 18, 2026 (Last updated: May 21, 2026) Pharmaphorum Regeneron’s LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price. Oncology Read full story Post navigation Previous: Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studiesNext: Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
